NEW HAVEN: Melinta Therapeutics, Inc. [Nasdaq: MLNT], a commercial-stage company discovering, developing, and commercializing novel antibiotics to treat serious bacterial infections, today announced the appointment of Lisa DeFrancesco as senior vice president of investor relations (IR) reporting to Dan Wechsler, president and chief executive officer.
DeFrancesco is a seasoned healthcare industry executive, with 18 years of experience in investor relations, finance and communications. She joins Melinta from Allergan [NYSE: AGN] where she served most recently as vice president of IR.
“We are thrilled to have Lisa join our expanding executive leadership team as Melinta continues to grow and evolve as a world-leading antibiotics company,” stated Dan Wechsler, president and chief executive officer. “Her deep experience integrating IR, corporate finance, sell-side equity research, communications and proven track record in investor relations, will help us to capitalize on the many opportunities that lie ahead as we build a bigger, better Melinta, focused on delivering value to all of our stakeholders.”